Methodology of a new inflammatory arthritis registry: TReasure
Göster/ Aç
Tarih
2018Yazar
Tufan, Muge Aydin
Kalyoncu, Umut
Tascilar, Etem Koray
Ertenli, Ali Ihsan
Dalkilic, Huseyin Ediz
Bes, Cemal
Kucuksahin, Orhan
Kasifoglu, Timucin
Alpay Kanitez, Nilufer
Emmungil, Hakan
Kimyon, Gezmis
Yasar Bilge, Nafize Sule
Akar, Servet
Atagunduz, Mehmet Pamir
Koca, Suleyman Serdar
Ates, Askin
Yazisiz, Veli
Terzioglu, Ender
Ersozlu, Emine Duygu
Tufan, Muge Aydin
Cinar, Muhammet
Mercan, Ridvan
Sahin, Ali
Erten, Sukran
Pehlivan, Yavuz
Yilmaz, Sedat
Kelesoglu Dincer, Ayse Bahar
Gercik, Onay
Coskun, Belkis Nihan
Yagiz, Burcu
Kaymaz Tahra, Sema
Aksoy, Aysun
Karadag, Omer
Kilic, Levent
Kiraz, Sedat
Üst veri
Tüm öğe kaydını gösterÖzet
Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients.
Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data.
Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.
Bağlantı
http://journals.tubitak.gov.tr/medical/issues/sag-18-48-4/sag-48-4-23-1807-200.pdfhttp://hdl.handle.net/11727/3171
Koleksiyonlar
- PubMed Açık Erişimli Yayınlar [1472]
- PubMed İndeksli Yayınlar Koleksiyonu [2382]
- Scopus İndeksli Yayınlar Koleksiyonu [3057]
- Tıp Fakültesi / Faculty of Medicine [5869]
- TR-Dizin Açık Erişimli Yayınlar [896]
- TR-Dizin İndeksli Yayınlar Koleksiyonu [984]
- Wos Açık Erişimli Yayınlar [2402]
- Wos İndeksli Yayınlar Koleksiyonu [4123]